Additionally, identifying biomarkers, such as HbA1c and C-reactive protein, which may indicate susceptibility to HS in patients with T1D, will facilitate the development of surveillance and therapeutic strategies targeting shared pathways, including those affected by TNF-α inhibitors [38] and GLP-1 receptor agonists. The gene discussed is TNF; the disease is type 1 diabetes mellitus.